產(chǎn)品編號 | bs-46010P |
英文名稱 | Recombinant SARS-Cov-2 Spike S1 protein (D614G), His & Avi (HEK293) |
中文名稱 | 重組SARS冠狀病毒2 Spike突變蛋白S1 (D614G)(His-Avi) |
別 名 | SARS-CoV-2 spike protein; 2019-nCOV Spike protein; Spike glycoprotein; Spike protein S1; Surface glycoprotein; Spike protein RBD; SPIKE_SARS2; 2019-nCOV Spike S1(D614G), Recombinant (His-Avi Tag); Recombinant SARS-Cov-2 Spike S1 protein (D614G), His & Avi (HEK293) 突變型新冠蛋白; 新冠病毒S蛋白突變體(D614G); 重組新冠病毒 Spike突變蛋白RBD(D614G); 新型冠狀病毒Spike突變體蛋白; |
理論分子量 | 77.9kDa |
檢測分子量 | 110-130 kDa |
性 狀 | Lyophilized or Liquid |
濃 度 | >0.5 mg/ml |
物 種 | SARS-Cov-2 |
序 列 | 14-683/1273 |
純 度 | >95% as determined by SDS-PAGE |
純化方法 | AC |
內(nèi)毒素 | Not analyzed |
表達系統(tǒng) | HEK293 cell |
活性 | Yes |
標簽 | His & Avi |
緩 沖 液 | Lyophilized from 0.22 um filtered solution in PBS (pH=7.4). Normally 5% trehalose is added as protectant before lyophilization. |
保存條件 | Stored at -70℃ or -20℃. Avoid repeated freeze/thaw cycles. |
注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
產(chǎn)品介紹 | The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in the context of a soluble S ectodomain construct. SWISS: P0DTC2 Gene ID: 43740568 |
我要詢價
*聯(lián)系方式:
(可以是QQ、MSN、電子郵箱、電話等,您的聯(lián)系方式不會被公開)
*內(nèi)容: